Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.012
Meng Wang, Lei Wang
Lung ventilation/perfusion (V/Q) imaging is the recommended diagnostic technique for pulmonary embolism. With the development of imaging equipments, radiopharmaceuticals and new quantitative techniques, lung V/Q imaging has been increasingly used in other lung diseases. This article reviews the clinical application of lung V/Q imaging in non-pulmonary embolic diseases. Key words: Lung disease; Ventilation/perfusion imaging; Trends
{"title":"Application of lung ventilation/perfusion imaging in non-pulmonary embolic diseases","authors":"Meng Wang, Lei Wang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.012","url":null,"abstract":"Lung ventilation/perfusion (V/Q) imaging is the recommended diagnostic technique for pulmonary embolism. With the development of imaging equipments, radiopharmaceuticals and new quantitative techniques, lung V/Q imaging has been increasingly used in other lung diseases. This article reviews the clinical application of lung V/Q imaging in non-pulmonary embolic diseases. \u0000 \u0000 \u0000Key words: \u0000Lung disease; Ventilation/perfusion imaging; Trends","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"553-556"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45233019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.016
Liang Guan, Yi-Yin Huang, Shuaijun Chen, Xueqin Deng
{"title":"Multidisciplinary and outpatient clinic experience in the perioperative treatment of Graves hyperthyroidism patients with several complications","authors":"Liang Guan, Yi-Yin Huang, Shuaijun Chen, Xueqin Deng","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.016","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"568-569"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44652088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.001
J. Ge, P. Wu, Y. Guan, Huiwei Zhang, Ling Li, Jiaying Lu, Likun Yang, Wei Lin, C. Zuo
Objective To study the effect of short-term treatment of subthalamic nucleus (STN) deep brain stimulation (DBS) on cerebral glucose metabolism in patients with Parkinson′s disease (PD) and its relationship with the change of brain motor-related nerve pathways. Methods Five patients (2 males, 3 females; age: (63.6±11.8) years) with PD who underwent STN DBS between January 2014 and December 2018 were enrolled in this study. All patients underwent 18F-fluorodeoxyglucose (FDG) PET in " DBS-off" state before and 3 months after operation. Quantitative expression of PD-related metabolic pattern (PDRP) were calculated by scaled subprofile model/principal component analysis (SSM/PCA) on PET images. Brain regions with changes of glucose metabolism after DBS were located by statistical parametric mapping (SPM) paired t test. Results Compared with pre-operation, PDRP expression (5.1±1.3 vs 2.9±1.8) and unified Parkinson′s disease rating scale (UPDRS) motor score (50.2±8.2 vs 28.0±5.4) of PD patients were significantly decreased 3 months after STN DBS (t values: 6.17 and 3.88, both P<0.05). After DBS, the glucose metabolism of bilateral globus pallidus/putamen, caudate nucleus, thalamus, insula, pons and cerebellum decreased, while the glucose metabolism of bilateral prefrontal motor area and parietooccipital lobe increased (t=3.75, P<0.01). Conclusions Short-term STN DBS therapy can inhibit the cortico-striatum-pallidum-hypothalamus-cortex motor loop, which is abnormally excitable in the brain of PD. PDRP, as an imaging characterization of the regulation of this loop, is expected to become an imaging marker for monitoring the treatment of PD. Key words: Parkinson disease; Deep brain stimulation; Subthalamic nucleus; Positron-emission tomography; Deoxyglucose
目的探讨丘脑底核（STN）脑深部刺激（DBS）短期治疗对帕金森病（PD）患者脑糖代谢的影响及其与脑运动相关神经通路变化的关系。方法5例PD患者（2男3女；年龄：（63.6±11.8）岁，于2014年1月至2018年12月接受STN DBS治疗。所有患者在术前和术后3个月均接受18F-氟脱氧葡萄糖（FDG）PET“DBS关闭”状态检查。通过缩放子文件模型/主成分分析（SSM/PCA）在PET图像上计算PD相关代谢模式（PDRP）的定量表达。采用统计参数映射（SPM）配对t检验定位DBS后糖代谢变化的脑区。结果与术前相比，STN DBS后3个月PD患者PDRP表达（5.1±1.3 vs 2.9±1.8）和帕金森病统一评定量表（UPDRS）运动评分（50.2±8.2 vs 28.0±5.4）显著降低（t值分别为6.17和3.88，均P<0.05），脑桥和小脑减少，而双侧前额叶运动区和顶枕叶的糖代谢增加（t=3.75，P<0.01），有望成为监测帕金森病治疗的影像学标志物。关键词：帕金森病；脑深部刺激；丘脑下核；正电子发射断层扫描；脱氧葡萄糖
{"title":"Effects of short-term deep brain stimulation in subthalamic nucleus on glucose metabolism in Parkinson′s disease","authors":"J. Ge, P. Wu, Y. Guan, Huiwei Zhang, Ling Li, Jiaying Lu, Likun Yang, Wei Lin, C. Zuo","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.001","url":null,"abstract":"Objective \u0000To study the effect of short-term treatment of subthalamic nucleus (STN) deep brain stimulation (DBS) on cerebral glucose metabolism in patients with Parkinson′s disease (PD) and its relationship with the change of brain motor-related nerve pathways. \u0000 \u0000 \u0000Methods \u0000Five patients (2 males, 3 females; age: (63.6±11.8) years) with PD who underwent STN DBS between January 2014 and December 2018 were enrolled in this study. All patients underwent 18F-fluorodeoxyglucose (FDG) PET in \" DBS-off\" state before and 3 months after operation. Quantitative expression of PD-related metabolic pattern (PDRP) were calculated by scaled subprofile model/principal component analysis (SSM/PCA) on PET images. Brain regions with changes of glucose metabolism after DBS were located by statistical parametric mapping (SPM) paired t test. \u0000 \u0000 \u0000Results \u0000Compared with pre-operation, PDRP expression (5.1±1.3 vs 2.9±1.8) and unified Parkinson′s disease rating scale (UPDRS) motor score (50.2±8.2 vs 28.0±5.4) of PD patients were significantly decreased 3 months after STN DBS (t values: 6.17 and 3.88, both P<0.05). After DBS, the glucose metabolism of bilateral globus pallidus/putamen, caudate nucleus, thalamus, insula, pons and cerebellum decreased, while the glucose metabolism of bilateral prefrontal motor area and parietooccipital lobe increased (t=3.75, P<0.01). \u0000 \u0000 \u0000Conclusions \u0000Short-term STN DBS therapy can inhibit the cortico-striatum-pallidum-hypothalamus-cortex motor loop, which is abnormally excitable in the brain of PD. PDRP, as an imaging characterization of the regulation of this loop, is expected to become an imaging marker for monitoring the treatment of PD. \u0000 \u0000 \u0000Key words: \u0000Parkinson disease; Deep brain stimulation; Subthalamic nucleus; Positron-emission tomography; Deoxyglucose","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"513-517"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45018191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.014
Wu-jian Mao
18F-fluorodeoxyglucose (FDG) PET/CT offers excellent diagnostic performance on colorectal cancer liver metastases(CRCLM) in terms of sensitivity and specificity, and can comprehensively identify the presence of extrahepatic metastases and provide valuable information for the treatment decision making. 18F-FDG PET/CT can also be used in the early assessment of response to CRCLM therapy and survival prediction. However, the diagnostic value of PET/CT is limited for lesions with diameter within 10 mm or with activity inhibited strongly by chemotherapy. PET combined with contrast enhanced CT may have potential value in improving diagnostic sensitivity for CRCLM. Key words: Colorectal neoplasms; Neoplasm metastasis; Liver; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose
{"title":"Value of 18F-FDG PET/CT in the diagnosis and treatment of colorectal cancer liver metastases","authors":"Wu-jian Mao","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.014","url":null,"abstract":"18F-fluorodeoxyglucose (FDG) PET/CT offers excellent diagnostic performance on colorectal cancer liver metastases(CRCLM) in terms of sensitivity and specificity, and can comprehensively identify the presence of extrahepatic metastases and provide valuable information for the treatment decision making. 18F-FDG PET/CT can also be used in the early assessment of response to CRCLM therapy and survival prediction. However, the diagnostic value of PET/CT is limited for lesions with diameter within 10 mm or with activity inhibited strongly by chemotherapy. PET combined with contrast enhanced CT may have potential value in improving diagnostic sensitivity for CRCLM. \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; Neoplasm metastasis; Liver; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"560-563"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49076623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.003
Xia-lian Li, Xinyu Wu, Minmin Tang, Bo Li, Ye Long, Xiaofei Li, Junling Xu
Objective To investigate the regularity and clinical significance of abnormal bone uptake of 99Tcm-methylene bisphosphonate (MDP) in benign and malignant lesions. Methods A retrospective analysis was performed on 266 patients (132 males, 134 females, age range: 8-85 years) with abnormal uptake of 99Tcm-MDP in extraosseous tissues from September 2015 to March 2018. The final diagnosis of abnormal uptake was made according to the histopathology, laboratory and related imaging examination (CT, MRI, ultrasound, SPECT/CT or PET/CT imaging) results within 2 weeks after 99Tcm-MDP imaging. Regularity of abnormal 99Tcm-MDP uptake was comprehensively analyzed. Differences between benign and malignant groups were compared by χ2 test or Fisher exact test. Results Abnormal 99Tcm-MDP uptake in extraosseous tissues in 232 patients (87.2%, 232/266) were confirmed as malignant lesions and those in 34 patients (12.8%, 34/266) were benign. There were no significant differences in gender (χ2=0.611, P>0.05), age (P=0.584), and location (P=0.118) between benign and malignant lesions, but the involvement was significantly different (χ2=19.515, P<0.05). There were significant differences between single focus and diffuse foci of single organ, diffuse foci of single organ and multiple foci groups (χ2=8.959, 19.325, both P<0.01). Conclusions The detection rate of malignancy among foci with abnormal 99Tcm-MDP uptake in extraosseous tissues is high, and the malignancy may relate with the involvement of foci. When extraosseous uptake is found, clinical information and related examination results should be comprehensively analyzed and the malignancy should be taken into account. Key words: Skeleton; Neoplasms; Diagnosis, differential; Tomography, emission-computed, single-photon; Tomography, X-ray computed; Technetium Tc 99m medronate
{"title":"Diagnostic value and clinical significance of abnormal uptake in extraosseous tissue for differentiating benign from malignant lesions","authors":"Xia-lian Li, Xinyu Wu, Minmin Tang, Bo Li, Ye Long, Xiaofei Li, Junling Xu","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.003","url":null,"abstract":"Objective \u0000To investigate the regularity and clinical significance of abnormal bone uptake of 99Tcm-methylene bisphosphonate (MDP) in benign and malignant lesions. \u0000 \u0000 \u0000Methods \u0000A retrospective analysis was performed on 266 patients (132 males, 134 females, age range: 8-85 years) with abnormal uptake of 99Tcm-MDP in extraosseous tissues from September 2015 to March 2018. The final diagnosis of abnormal uptake was made according to the histopathology, laboratory and related imaging examination (CT, MRI, ultrasound, SPECT/CT or PET/CT imaging) results within 2 weeks after 99Tcm-MDP imaging. Regularity of abnormal 99Tcm-MDP uptake was comprehensively analyzed. Differences between benign and malignant groups were compared by χ2 test or Fisher exact test. \u0000 \u0000 \u0000Results \u0000Abnormal 99Tcm-MDP uptake in extraosseous tissues in 232 patients (87.2%, 232/266) were confirmed as malignant lesions and those in 34 patients (12.8%, 34/266) were benign. There were no significant differences in gender (χ2=0.611, P>0.05), age (P=0.584), and location (P=0.118) between benign and malignant lesions, but the involvement was significantly different (χ2=19.515, P<0.05). There were significant differences between single focus and diffuse foci of single organ, diffuse foci of single organ and multiple foci groups (χ2=8.959, 19.325, both P<0.01). \u0000 \u0000 \u0000Conclusions \u0000The detection rate of malignancy among foci with abnormal 99Tcm-MDP uptake in extraosseous tissues is high, and the malignancy may relate with the involvement of foci. When extraosseous uptake is found, clinical information and related examination results should be comprehensively analyzed and the malignancy should be taken into account. \u0000 \u0000 \u0000Key words: \u0000Skeleton; Neoplasms; Diagnosis, differential; Tomography, emission-computed, single-photon; Tomography, X-ray computed; Technetium Tc 99m medronate","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"522-525"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45810786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.013
Jiao Wang, Jianming Li, Shuai Li
PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. Key words: Myocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends
PET心肌灌注成像（MPI）越来越多地用于冠状动脉疾病（CAD）的无创检测和评估。然而，常见的PET MPI试剂（15O-H2O、13N-NH3·H2O、82Rb）在临床上的广泛应用受到其固有缺陷的限制。18F Flurpiridaz的开发开辟了正电子血流显像剂的新领域。临床前和临床试验的初步结果表明，18F Flurpiridaz作为一种理想的PET MPI试剂具有重要的特性（高心肌摄取、高灌注缺陷分辨率、缓慢的心肌清除率、稳定的靶/非靶比值和定量心肌流量分析能力），具有良好的临床应用前景。本文综述了18F Flurpiridaz PET MPI的应用现状和进展。关键词：心肌灌注成像；正电子发射断层扫描；吡啶；氟放射性同位素；趋势
{"title":"Research progress of 18F-Flurpiridaz PET myocardial perfusion imaging","authors":"Jiao Wang, Jianming Li, Shuai Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.013","url":null,"abstract":"PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. \u0000 \u0000 \u0000Key words: \u0000Myocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"557-559"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46062305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.002
P. Chen, Wei Chen, Xiaofeng Li
Objective To investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the diagnosis of different pathological types of primary osseous malignant tumors (POMT) in patients over 40 years old. Methods Fifty-two patients (30 males, 22 females, median age: 60(41-81)years) with POMT who underwent 18F-FDG PET/CT and were pathologically confirmed from January 2013 to May 2018 in Cancer Hospital of Tianjin Medical University were reviewed. The region of interest was drawn and the standardized uptake value (SUV) was automatically measured. The SUV in different pathological types of POMT was compared using one-way analysis of variance or two-sample t test. Results The 52 POMT included 22 sarcomas, 16 isolated myelomas (IM), and 14 primary bone lymphomas (PBL). The SUV in PBL was significantly higher that than in sarcomas and IM with the maximum SUV (SUVmax) of 21.6±12.4, 13.5±7.7 and 9.0±6.4 respectively(F=7.56, P<0.01), and the mean SUV (SUVmean) of 12.9±7.8, 7.5±4.5, and 5.6±4.4, respectively(F=6.92, P<0.01). In the sarcoma group, the SUV of undifferentiated sarcomas was significantly higher than that of other well-differentiated sarcomas (SUVmax: 21.1±5.4 vs 11.3±6.9, SUVmean: 11.8±3.3 vs 6.3±4.1; t=-2.92, -2.71, both P<0.01). The growth pattern of sarcomas and IM was different on CT images. Conclusions The FDG uptake of PBL is higher than that of other pathological types. CT features are helpful for the differential diagnosis of POMT in 18F-FDG PET/CT. Key words: Bone neoplasms; Middle aged; Aged; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose
目的探讨18f -氟脱氧葡萄糖(FDG) PET/CT对40岁以上不同病理类型原发性骨恶性肿瘤(POMT)的诊断价值。方法回顾2013年1月至2018年5月天津医科大学肿瘤医院经18F-FDG PET/CT病理证实的52例POMT患者，其中男30例，女22例，中位年龄:60(41-81)岁。绘制感兴趣区域并自动测量标准化摄取值(SUV)。采用单因素方差分析或双样本t检验比较不同病理类型POMT的SUV。结果52例POMT包括22例肉瘤，16例分离性骨髓瘤(IM)， 14例原发性骨淋巴瘤(PBL)。PBL的SUV显著高于肉瘤和IM，最大SUV (SUVmax)分别为21.6±12.4、13.5±7.7和9.0±6.4 (F=7.56, P<0.01)，平均SUV (SUVmean)分别为12.9±7.8、7.5±4.5和5.6±4.4 (F=6.92, P<0.01)。在肉瘤组中，未分化肉瘤的SUV明显高于其他高分化肉瘤(SUVmax: 21.1±5.4 vs 11.3±6.9,SUVmean: 11.8±3.3 vs 6.3±4.1;t=-2.92， -2.71, P均<0.01)。肉瘤和IM在CT上的生长模式不同。结论PBL的FDG摄取高于其他病理类型。CT表现有助于18F-FDG PET/CT对POMT的鉴别诊断。关键词:骨肿瘤;中年;岁的;正电子发射断层扫描;断层扫描，x射线计算机;脱氧葡萄糖
{"title":"Diagnosis of primary osseous malignant tumors with 18F-FDG PET/CT in patients over 40 years old","authors":"P. Chen, Wei Chen, Xiaofeng Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.002","url":null,"abstract":"Objective \u0000To investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the diagnosis of different pathological types of primary osseous malignant tumors (POMT) in patients over 40 years old. \u0000 \u0000 \u0000Methods \u0000Fifty-two patients (30 males, 22 females, median age: 60(41-81)years) with POMT who underwent 18F-FDG PET/CT and were pathologically confirmed from January 2013 to May 2018 in Cancer Hospital of Tianjin Medical University were reviewed. The region of interest was drawn and the standardized uptake value (SUV) was automatically measured. The SUV in different pathological types of POMT was compared using one-way analysis of variance or two-sample t test. \u0000 \u0000 \u0000Results \u0000The 52 POMT included 22 sarcomas, 16 isolated myelomas (IM), and 14 primary bone lymphomas (PBL). The SUV in PBL was significantly higher that than in sarcomas and IM with the maximum SUV (SUVmax) of 21.6±12.4, 13.5±7.7 and 9.0±6.4 respectively(F=7.56, P<0.01), and the mean SUV (SUVmean) of 12.9±7.8, 7.5±4.5, and 5.6±4.4, respectively(F=6.92, P<0.01). In the sarcoma group, the SUV of undifferentiated sarcomas was significantly higher than that of other well-differentiated sarcomas (SUVmax: 21.1±5.4 vs 11.3±6.9, SUVmean: 11.8±3.3 vs 6.3±4.1; t=-2.92, -2.71, both P<0.01). The growth pattern of sarcomas and IM was different on CT images. \u0000 \u0000 \u0000Conclusions \u0000The FDG uptake of PBL is higher than that of other pathological types. CT features are helpful for the differential diagnosis of POMT in 18F-FDG PET/CT. \u0000 \u0000 \u0000Key words: \u0000Bone neoplasms; Middle aged; Aged; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"518-521"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43993299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.007
Zhijian Liu, T. Geng, Ming-Liang Wang, G. Dong, Hai Geng, M. Zeng
{"title":"18F-FDG PET/CT imaging characteristics of focal peliosis hepatis","authors":"Zhijian Liu, T. Geng, Ming-Liang Wang, G. Dong, Hai Geng, M. Zeng","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.007","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"542-543"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46337947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.010
Na Liu
{"title":"Graves disease after 131I therapy in a case of autonomously functioning thyroid adenoma","authors":"Na Liu","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.010","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"548-549"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46141434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.09.005
Y. Long, Cai-xia An
Objective To compare the clinical features of papillary thyroid microcarcinoma (PTMC) and non-microcarcinoma papillary thyroid carcinoma (PTC). Methods Clinical data of 522 patients (156 males, 366 females, age: 16-77 years) with PTC treated with 131I from January 2014 to September 2018 were analyzed retrospectively. Patients were divided into PTMC group (46 males, 139 females, age: (38.5±6.5) years; tumor diameter≤1.0 cm) and non-microcarcinoma PTC group (110 males, 227 females, age: (40.5±4.5) years; tumor diameter>1.0 cm). General information and TNM status of patients were compared. The t′ test and χ2 test were used to analyze the data. Results Patients was relatively young in PTMC group (t′=2.20, P 0.05; mostly females). The incidence of extraglandular invasion in PTMC group was significantly lower than that in PTC group (33.51%(62/185) vs 56.08%(189/337); χ2=24.37, P 0.05). Conclusions Clinical characteristics of PTC can be influenced by tumor diameter. The features of primary tumor and lymph node metastasis between patients with moderate- and high-risk PTMC and non-microcarcinoma PTC patients are similar, which suggests that 131I therapy is necessary to patients with moderate- and high-risk PTMC. Key words: Thyroid neoplasms; Carcinoma, papillary; Radiotherapy; Iodine radioisotopes
{"title":"Characteristics of 185 thyroid micropapillary carcinoma patients undergoing 131I treatment","authors":"Y. Long, Cai-xia An","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.005","url":null,"abstract":"Objective \u0000To compare the clinical features of papillary thyroid microcarcinoma (PTMC) and non-microcarcinoma papillary thyroid carcinoma (PTC). \u0000 \u0000 \u0000Methods \u0000Clinical data of 522 patients (156 males, 366 females, age: 16-77 years) with PTC treated with 131I from January 2014 to September 2018 were analyzed retrospectively. Patients were divided into PTMC group (46 males, 139 females, age: (38.5±6.5) years; tumor diameter≤1.0 cm) and non-microcarcinoma PTC group (110 males, 227 females, age: (40.5±4.5) years; tumor diameter>1.0 cm). General information and TNM status of patients were compared. The t′ test and χ2 test were used to analyze the data. \u0000 \u0000 \u0000Results \u0000Patients was relatively young in PTMC group (t′=2.20, P 0.05; mostly females). The incidence of extraglandular invasion in PTMC group was significantly lower than that in PTC group (33.51%(62/185) vs 56.08%(189/337); χ2=24.37, P 0.05). \u0000 \u0000 \u0000Conclusions \u0000Clinical characteristics of PTC can be influenced by tumor diameter. The features of primary tumor and lymph node metastasis between patients with moderate- and high-risk PTMC and non-microcarcinoma PTC patients are similar, which suggests that 131I therapy is necessary to patients with moderate- and high-risk PTMC. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Carcinoma, papillary; Radiotherapy; Iodine radioisotopes","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"532-536"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45522616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：